

# Hedmark University College

Faculty of Public Health

# BRAGE

Hedmark University College's Open Research Archive

http://brage.bibsys.no/hhe/

This is the author's version of the article published in

European Journal of Clinical Pharmacology

The article has been peer-reviewed, but does not include the publisher's layout, page numbers and proof-corrections

Citation for the published paper:

Log, T., Skurtveit, S., Selmer, R.M., Tverdal, A., Furu, K. & Hartz, I. (2013). The association between prescribed opioid use for mothers and children: A record-linkage study. *European Journal of Clinical Pharmacology 69*(1), 111–118.

doi: http://dx.doi.org/10.1007/s00228-012-1312-8

The final publication is available at link.springer.com.

### TITLE PAGE

## <u>Title</u>

# Association of prescribed opioid use between mother and child - a record-linkage study

## Authors

Tomas Log<sup>1</sup>, Svetlana Skurtveit<sup>2,3</sup>, Randi Selmer<sup>2</sup>, Åge Tverdal<sup>2</sup>, Kari Furu<sup>1,2</sup>, Ingeborg Hartz<sup>2,4</sup>

<sup>1</sup> Department of pharmacoepidemiology and pharmacy practice, University of Tromsø, N- 9037 Tromsø, Norway

<sup>2</sup> Department of Pharmacoepidemiology, Division of Epidemiology, The Norwegian Institute of Public Health, Postboks 4404 Nydalen, 0403 Oslo, Norway

<sup>3</sup> The Norwegian Centre for Addiction Research, University of Oslo, Kirkeveien 166, 0407 Oslo, Norway

<sup>4</sup> Department of Health and Sports, Hedmark University College, Kirkeveien 47, 2418 Elverum, Norway

#### Corresponding author

Tomas Log Email: <u>tomas.log@uit.no</u> Phone: +47 77646156 Fax: +47 77646647 Postal address: Department of pharmacoepidemiology and pharmacy practice, University of Tromsø, N- 9037 Tromsø, Norway

#### Association of prescribed opioid use between mother and child – a record-linkage study

#### Absract

Repeated use of prescribed opioids may lead to serious side effects, and it is important to examine risk factors for repeated use. The aim of this study was to investigate the association between maternal use of prescribed opioids and the use of prescribed opioids by their offspring.

Data were drawn from two nationwide registers linked by the unique person identity numbers: the Norwegian Population and Housing Census in 2001 and the Norwegian Prescription Database (2004-2009). The study population consisted of 97,574 adolescents aged 15-16 years in 2001 and their mothers. Repeated use of opioids was defined as filling 4+ and 15+ prescriptions during 2004-2009 by the offspring and mothers, respectively. Non-steroidal anti-inflammatory drugs (NSAIDs) are not potentially addictive, and were used as a reference analgesic drug group.

The proportion of repeated users were higher among individuals whose mothers were registered with repeated use of opioids (8.4 %) compared to those with mothers without repeated use (2.4 %). Odds ratio was 3.1 (95% CI 2.7-3.6) when adjusted for mothers socioeconomic characteristics and the gender of the offspring. Low maternal socio-economic status increased the risk of repeated opioid use among their offspring. Maternal repeated use of NSAIDs increased the likelihood of repeated use of NSAIDs among offspring OR 1.8 (95% CI 1.7 – 2.0).

#### Introduction

Approximately 10 % of the Norwegian population received at least one opioid prescription for analgesia in 2009 [1]. This number has been increasing steadily over the years parallel to that of many other developed countries [2-10]. Increased efforts to address the assumed under-treatment of pain [11] may be one explanation, as extensive literature has shown that pain management is critical in order to achieve a favorable quality of life and improve medical outcome [12].

Opioids have been the mainstay of pain treatment for thousands of years, and remain so today [13]. Its use has been and still is the focus of considerable debate due to its double-edged nature in terms therapeutic effect and serious side effects. Prescription opioids are highly effective when used properly [14] and are generally of low organ toxicity [15], but long-term use may be problematic because of the risk of addiction and misuse [14]. As it is unlikely that other classes of analgesic drugs will supersede the opioids in the very near future [11] it is important to identify those at high risk of developing problematic use of opioids before initiating treatment. One way to achieve this is to identify potential risk factors through epidemiological studies.

Tsuang and colleagues recognize drug abuse as the culmination of a series of transitions of drug involvement from drug exposure to drug abuse. Drug abuse is preceded by a series of aquisititon steps that are necessary, but not sufficient for its development [16]. In developed countries therapeutic

prescription of opioids adds to several steps of this chain of transitions; exposure, sporadic use and regular use. In that context, use of prescribed opioids plays an important role in the potential development of opioid abuse. Drugs abuse is thought to be a result of both genetic and environmental risk factors [17] which is supported by evidence that liability to illicit drug use and abuse aggregates in families [18]. To our knowledge, updated information on the influence of maternal use of prescribed opioids on prescribed use in their offspring, as a separate factor and in relation to other socioeconomic characteristics of the household, is limited. Therefore, it would be interesting – and important in a public health perspective – to investigate the reproduction of use of potentially addictive prescription drugs across generations. In Norway all citizens are assigned a unique 11-digit identification number, enabling linkage of available register information on drug use and socioeconomic characteristics, on an individual level [19]. It is also possible to link together members within the same household. Thus, based on nationwide register information, the aim of this study were to investigate the association between maternal use of prescribed opioids and the use of prescribed opiods by their offspring.

#### Methods

Data from The Population and Housing Census in 2001 (Census 2001) and the Norwegian Prescription Database (NorPD) were linked by using the unique 11-digit identification number, assigned to all individuals living in Norway. The record linkage was approved by the Norwegian Data Inspectorate and has been endorsed by the Regional Committee for Medical Research Ethics.

#### The Population and Housing Census in 2001 – information on socioeconomic data

Information on socioeconomic variables was retrieved from the nationwide population and housing census in Norway 2001 (Statistics Norway), performed November 3<sup>rd</sup> 2001 [20]. These variables are based on information from several administrative registers and contain information on all citizens living in Norway. Each individual is registered with a family number, enabling linkage of individuals within the same household. In this context, individuals registered within the same household do not necessarily imply a biological family relationship between individuals. However, according to administrative registers 97.6 % of all children aged 0-17 years were living with their biological mother in Norway in 2000, at the time when the nationwide population and housing census was performed (Statistics Norway, 2001). Thus, adult females within the household will be referred to as mothers throughout the paper. The following variables were included in our analysis; mothers educational level, mothers activity status/labour force participation (employed, unemployed, in education, or receipt of national insurance benefit (disability-, retirement- or survivor pension)), marital status and age.

#### The Norwegian Prescription Database – information on drug use

Prescription data on analgesics during 2004–2009 were drawn from the NorPD, which covers all of Norway's 4.8 million inhabitants. From January 1, 2004, all pharmacies in Norway have been obliged by law to send in electronic data on all redeemed prescriptions to the Norwegian Institute of Public

Health [19]. NorPD contains information on all individuals who have received prescription drugs dispensed at pharmacies. All prescriptions, reimbursed or not, are stored in the database and the drugs are classified according to the anatomical therapeutic chemical (ATC) classification [21]. Data on opioids (ATC code N02A, main outcome variable) and non-steroidal anti-inflammatory drugs (NSAIDs, ATC code M01A, comparator) were used. Codeine, tramadol and dextropropoxyphene make up the weak N02A-opioids on the Norwegian marked, while the following strong N02A-opioids are available: morphine, hydromorphone, oxycodone, ketobemidone, phetidine, fentanyl, buprenorphine and tapentadol [22]. All N02A-opioids require prescriptions in Norway. Parallel to opioid drugs, NSAIDs have analgesic properties, but without the potential of being addictive. For this reason NSAIDs was used as reference. The data collected were: patient unique identifying number (encrypted), sex, age, age at death in case of death during the period, reimbursement code, the dispensing date and drug information (ATC code and number of defined daily doses (DDD)).

The outcome variable, repeated use of opioids among offspring, was defined as receiving four or more opioid prescriptions during 2004–2009. By using this limit the repeated users consist of the highest 10 percentile of opioid users. This cut-off was chosen to exclude users who received opioids for minor incidents such as dentistry and accidents. Repeated use among mothers' was defined similarly by the highest 10 percentile, which gave a cut-off of 15 or more prescriptions. The same 10 percentile cut-off was used for the comparator. Reimbursement codes held in the database were used to identify patients receiving analgesics for cancer treatment.

#### The study population

Our analysis are restricted to data on citizens aged 15-16 years in 2001 and their mothers, participating in the nationwide population and housing census in Norway in 2001 and registered living in the same household that year. Children born in 1985-86 were selected (n= 108,163), of whom 285 were excluded because of situations such as; registered as parents themselves, not living in a private household, or living in cohabitation (Figure 1). The mother was defined as the oldest female person registered with the same family number as the 15-16 year old. This may have led to misclassifying grandmothers as mothers, but only 5 of the classified mothers were > 50 years at the time of the classified offspring's birth. In total 657 were excluded, in whom the oldest female or male registered in the same household was 15 years or younger at time of birth. In families with more than one 15-16 year old, only the firstborn were included. The 107,221 15-16 year olds were distributed in 104,214 families, in which 5,725 were excluded due to being registered living without their mothers and 915 were excluded because the mother and/or their offspring received opioids to treat cancer related pain. The remaining 97,574 mother-child pairs were included in the analysis. The outcome variable, repeated use of opioids among offspring, was obtained during 2004-2009, when the children were 18-24 years of age.

#### **Statistics**

Odds ratios (OR) with 95% confidence intervals (CI) for variables potentially associated with opioid use, were estimated by logistic regression. Maternal characteristics such as mothers' use of opioids,

educational level, activity status/labour force participation, marital status and age were included in the model as independent variables together with the offspring's gender. In total, 95,819 of the 97,574 families included in the logistic regression had complete data on all the variables in the analysis (1.8 % missing). All analyses were done using SPSS 15.0 for Windows. Cochrane-Armitage test for linear trend was used to examine a possible dose-response relationship between the proportion of offspring opioid users with the number of maternal opioid prescriptions. Level of significance was set to p<0.05.

#### Results

Table 1 shows the socioeconomic characteristics of the mothers according to opioid use status. Overall a socioeconomic gradient was observed between mothers who were repeated opioid users during 2004-2009 compared to the rest of the study-population. Educational level was significantly lower among maternal users, a larger proportion of the maternal users were receivers of a disability pension, fewer were registered as employed as compared to the non users, and a higher proportion of the maternal users were not married (or a registered partner).

Of the 97,574 offspring eligible for analysis, 2,519 (2.6 %) were classified as repeated users of opioids during 2004-2009. The proportion of repeated users were higher among individuals whose mothers were registered with repeated use of opioids (8.4 %) compared to those with mothers without repeated use (2.4 %) (Table 2). Odds ratio was 3.7 decreasing to 3.1 when adjusting for other variables. Several of the variables based on characteristics of the mothers were independently associated with repeated opioid use among offspring: lower educational level, disability pensioner and not having a registered partner or husband. In addition, female offspring were more likely to use opioids repeatedly compared to males (Table 2).

A possible dose-response relationship was observed, with the proportion of offspring opioid users increasing with more frequent maternal opioid use. This was evident for various degrees of offspring opioid use (p<0.001 for all categories) (Figure 2).

A total of 5,267 offspring (5.4 %) were repeated users of NSAIDs during 2004-2009. Maternal repeated use of NSAIDs increased the likelihood of repeated use of NSAIDs among offspring OR 1.8 (1.7 - 2.0) (Table 3). Mothers' socioeconomic status was also predictive of repeated use of NSAIDs.

#### Discussion

Our study showed that repeated maternal use of opioids was associated with a threefold increased risk of repeated opioid use among their offspring. The proportion of offspring opioid users increased with increasing maternal opioid use, suggesting a dose-response relationship.

The association observed for repeated maternal and offspring use of NSAIDs may indicate that reproduction of drug use patterns is present for all classes of analgesics drugs. This may be due to inherited pain thresholds and/or habits of how to cope with- and treat pain.

We are not aware of other studies which specifically have examined the association between prescribed maternal and offspring opioid use. However, our results are in agreement with the findings in studies examining the association between parental and offspring illicit opioid use [17]. Evidence does suggest that the liability to illicit drug use and abuse aggregates in families, a phenomenon that may be explained by both genetic and environmental factors [18]. This might as well be the case with potentially addictive prescription drugs, as shown by a recent study conducted by Hartz and colleagues which found an association between maternal and offspring use of benzodiazepines/z-hypnotics, OR 1.9 (1.8 – 2.0) [23]. It is however, very important to emphasize that our cut-off points of 15+ prescriptions of opioids among mothers and 4+ prescriptions among their offspring do not indicate problematic use of opioids or abuse. It is not possible to separate appropriate from problematic use based on our data.

In terms of genetics, inheritable diseases that require or make opioid treatment more probable can explain some of the association observed in our study. In addition, inherited differences in pharmacokinetics and effect of opioids that increases the vulnerability to the development of problematic opioid use may be another contributing factor.

When taking environmental factors into account, being exposed to maternal opioid use may, as proposed by Tsuang, act as the first step on the way to opioid drug use. This is evident for illicit use and may also be true for therapeutic use. Additionally problematic use among offspring may be explained by negative life events associated with problematic maternal use [17].

Maternal characteristics indicating a lower socio-economic position (low education and disability pension) were independently associated to use of opioids among offspring. Considering the potentially harmful effect of these drugs, our results are in line with former research into health inequalities showing that lower socio-economic status is correlated with poorer habits of health behavior [24-25]. Thus, use of potentially addictive drugs may constitute yet another type of poor health behaviour, along with making unhealthy food choices, physical inactivity and smoking which is documented to be more prevalent among socio-economic disadvantaged groups [26].

Medicine use among young people in general is documented to be widespread and increasing [27-30]. Use of drugs for a variety of complaints among young females in particular, grows considerably during the teenage years [31]. One qualitative study exploring the use of analgesics revealed that young women relied on analgesics to cope with perceived pressures and social anxieties, as part of their attempt to meet everyday goals involving performance and participation [32]. Our study adds to the evidence that females are at a higher risk of becoming repeated users compared to men.

Even though many relevant confounders associated with opioid use are included in our model, we don't have any data on pain, the main indication of use, among the offspring. Thus, analgesic drug use increases significantly with more self-reported pain in this age group [33]. As a result, the observed difference may be explained by more cases of pain among offspring with mothers repeatedly using opioids.

We chose a 90-percentile cut-off for repeated use of opioids in order to exclude users who received opioids for minor incidents such as dentistry and accidents. A recent study from the United States showed that dentists were the main prescribers of opioids for patients aged 10-19 (31 %) and the second most frequent among those aged 20-29 (17 %) [10]. Lack of information on indication for opioid treatment makes it hard to determine whether our chosen cut-off point is ideal. In total, 24.5 % of the offspring retrieved at least one prescription on an opioid during the study period, while only 2.7 % received four or more prescriptions. Thus, repeated opioid use constituted about 10 % of the offspring opioid users in this study.

In this study repeated use of opioid included all opioids regardless of subclass. A more detailed analysis of patterns of use, including distinction between stronger/weaker and long-acting /short-acting opioids would have been desirable. Use of codeine in combination with paracetamol and tramadol do account for nearly the entire opioid consumption among younger generations [34]. As a result we could not stratify for strong/weak and long-acting/short-acting opioids due to few strong and long-acting opioid users.

Compliance is always an issue when using prescription based data. We don't have any data on the extent to which purchased drugs were actually taken. However, our data are based on dispensed drugs rather than prescribed which at least rules out primary non-compliance [35]. Finally our reference drug group may not be ideal as NSAIDs can be used either with or without a prescription, and we lack information on non-prescription use.

Other weaknesses include: 1) maternal characteristic valid in 2001 may have changed when data on drug use was collected in 2004-2009, 2) we do not know whether mother's drug use precedes that of the child, or vice versa.

During our six year study period 2.6 % of the offspring were classified as repeated users of opioids. Considering that cancer patients are excluded and that diseases requiring opioid therapy are quite rare in this age group, this number is high. In order to minimize the risk of problematic use of opioids, identifying factors associated to use is important. Our study suggests that repeated maternal use of opioids may be associated with repeated use of opioids among offspring.

No conflicts of interest are known to the authors.

#### References

[1] Norwegian Institute of Public Health. The Norwegian Prescription Database [Online] Available at: <u>http://www.reseptregisteret.no</u> Accessed 27 April, 2011.

[2] Berbatis CG, Sunderland VB, Bulsara M, Lintzeris N. Trends in licit opioid use in Australia, 1984-1998: comparative analysis of international and jurisdictional data. Med J Aust 2000; 173(10): 524–527.

[3] Clausen TG. International opioid consumption. Acta Anaesthesiol Scand 1997; 41: 162–165.

[4] De Conno F, Ripamonti C, Brunelli C. Opioid purchases and expenditure in nine western European countries: 'Are we killing off morphine?' Palliat Med 2005; 19(3): 179–184.

[5] Del Pozo JG, Carvajal A, Viloria JM, Velasco A, Del Pozo VG. Trends in the consumption of opioid analgesics in Spain. Higher increases as fentanyl replaces morphine. Eur J Clin Pharmacol 2008; 64: 411–415.

[6] Fredheim OM, Skurtveit S, Breivik H, Borchgrevink PC. Increasing use of opioids from 2004 to 2007—Pharmacoepidemiological data from a complete national prescription database in Norway. Eur J Pain 2010;14(3): 289–294.

[7] Gilson AM, Ryan KM, Joranson DE, Dahl JL. A reassessment of trends in the medical use and abuse of opioid analgesics and implications for diversion control: 1997–2002. J Pain Symptom Manage 2004; 28(2):176–188.

[8] Hamunen K, Paakkari P, Kalso E. Trends in opiod consumption in the Nordic countries 2002–2006.Eur J Pain 2009; 13(9): 954–962.

[9] Joranson DE, Ryan KM, Gilson AM, Dahl JL. Trends in medical use and abuse of opioid analgesics. JAMA 2000; 283(13): 1710–1714.

[10] Volkow ND, McLellan TA, Cotto JH, Karithanom M, Weiss SR. Characteristics of opioid prescriptions in 2009. JAMA. 2011 Apr 6;305(13):1299-1301.

[11] Walwyn WM, Miotto KA, Evans CJ. Opioid pharmaceuticals and addiction: The issues, and research directions seeking solutions. Drug Alc Dep 2010; 108: 156–165.

[12] Haanpaa ML, Backonja MM, Bennett MI, Bouhassira D, Cruccu G, Hansson PT, Jensen TS, Kauppila T, Rice AS, Smith BH, Treede RD, Baron R. Assessment of neuropathic pain in primary care. Am J Med 2009; 122: S13–21.

[13] Gutstein HB, Akil H, Opioid Analgesics, Hardman JG, Limbird LE, Gilman AG, Goodman &
 Gilman's The Pharmacological Basis of Therapeutics – 10<sup>th</sup> edition, McGraw-Hill, 2001, 569.

[14] Chou R. 2009 clinical guidelines from the American pain society and the American academy of pain medicine on the use of chronic opioid therapy in chronic noncancer pain. Pol Arch Med Wewn 2009; 119(7–8): 469–477.

[15] Raffa R. Pharmacological aspects of successful long-term analgesia. Clin Rheumatol 2006; 25 (Supp1): S9–15.

[16] Tsuang MT, Lyons MJ, Harley RM, Xian H, Eisen S, Goldberg J, True WR, Faraone V. Genetic and environmental influences on transitions in drug use. Behaviour Genetics 1999; 29(6): 473-479.

[17] Merikangas K, Stolar M, Stevens DE, Goulet J, Preisig MA, Fenton B, Zhang H, O'Malley SS,
Rounsaville BJ. Familial transmission of substance use disorders. Arch Gen Psychiatry 1998; 55: 973–979.

[18] Kendler KS, Aggen SH, Tambs K, Reichborn-Kjennerud T. Illicit psychoactive substance use, abuse and dependence in a population-based sample of Norwegian twins. Psycholical Medicine 2006; 36(7): 955-962.

[19] Furu K. Establishment of the nationwide Norwegian Prescription Database (NorPD)—new opportunities for research in pharmacoepidemiology in Norway. Nor J Epidemiol 2008; 18(2): 129–136.

[20] Utne H. The Population and Housing Census Handbook 2001. Statistics Norway, Department of Social Statistics, 2005/2 [Online] Available at: http://www.ssb.no/english/subjects/02/01/doc\_200502\_en/doc\_200502\_en.pdf Accessed 12 May,

nup://www.ssb.no/enghsh/subjects/02/01/doc\_200502\_en/doc\_200502\_en.pdf Accessed 12 May, 2011.

[21] WHO Collaborating Center for Drug Statistics Methodology. The ATC/DDD System [Online]. Available at: <u>http://www.whocc.no/atcddd/</u> Accessed 25 May, 2008.

[22] Felleskatalogen AS. Felleskatalogen. Available from: http://www.felleskatalogen.no

[23] Hartz I, Skille E, Selmer R, Tverdal Aa, Skurtveit S. Do patterns of maternal use of potentially addictive prescription drugs reproduce in their children? Pharmacoepidemiol Drug Saf 2011; 20(S1).

[24] Forbes A, Wainwright SP. On the methodological, theoretical and philosophical context of health inequalities research: a critique. Soc Sci Med 2001;53(6):801-816.

[25] Lindbladh E, Lyttkens CH. Habit versus choice: the process of decision-making in health-related behaviour. Soc Sci Med 2002;55(3):451-465.

 [26] Norwegian Ministry of Health and Care Services. Report No. 20 (2006–2007) to the Storting: National strategy to reduce social inequalities in health [Online] Available at: <u>http://www.regjeringen.no/pages/1975150/PDFS/STM200620070020000EN\_PDFS.pdf</u> Accessed 10 May, 2011.

[27] Hansen EH, Holstein BE, Due P. Time trends in medicine use among adolescents in industrialised countries. Eur J Public Health 2003; 13:43.

[28] Holstein B, Andersen A, Due P, Hansen EH. [Children's and adolescent's use of medicine for aches and psychological problems: secular trends from 1988 to 2006]. Ugeskr Laeger 2009; 171(1–2): 24–28.

[29] Holstein BE, Holme Hansen E, Due P, Birna Almarsdottir A. Selfreported medicine use among
11- to 15-year-old girls and boys in Denmark 1988—1998. Scand J Public Health 2003; 31(5): 334–341.

[30] Hsia Y, Maclennan K. Rise in psychotropic drug prescribing in children and adolescents during 1992-2001: a population-based study in the UK. Eur J Epidemiol 2009; 24(4): 211–216.

[31] Hansen EH, Holstein BE, Due P, Currie CE. International survey of self-reported medicine use among adolescents. Ann Pharmacother 2003; 37(3): 361–366.

[32] Hansen DL, Hansen EH, Holstein BE. Young women's use of medicines: autonomy and positioning in relation to family and peer norms. Health (London) 2009; 13(4): 467–485.

[33] Log T, Hartz I, Handal M, Tverdal A, Furu K, Skurtveit S. The association between smoking and subsequent repeated use of prescribed opioids among adolescents and young adults--a population-based cohort study. Pharmacoepidemiol Drug Saf. 2011;20(1):90-98.

[34] Norwegian Institute of Public Health. Norwegian Prescription Database. [Internet]. Available from: http://www.norpd.no/.

[35] Beardon PH, McGilchrist MM, McKendrick AD, McDevitt DG, MacDonald TM. Primary noncompliance with prescribed medication in primary care. BMJ 1993;307(6908): 846–848.

# **Figures and tables**

Figure 1: Flow chart of the study population. Collected from the Population and Housing Census in 2001



Figure 2: The proportion of opioid users (various degrees) among offspring based on maternal use of opioids



	Repeated maternal use of opioids during 2004-09 <sup>1</sup>				
	<b>No</b> (N = 94423)	<b>Yes</b> (N = 4066)	p-value		
Mother age (mean(SD))	43.0 (5.0)	42.0 (5.3)	< 0.001		
Mother educational level <sup>2</sup>			< 0.001		
low (junior high school)	11.4 % (10544/92763)	21.8 % (865/3962)			
medium (senior high school)	58.8 % (54561/92763)	63.3 % (2508/3962)			
high (college, university)	29.8 % (27658/92763)	14.9 % (589/3962)			
Mother actitivity status <sup>3</sup>			< 0.001		
employed	83.9 % (79206/94413)	59.3 % (2411/4066)			
unemployed	1.3 % (1219/94413)	2.0 % (82/4066)			
student	1.5 % (1402/94413)	2.0 % (80/4066)			
disability pensioner	3.3 % (3099/94413)	19.6 % (796/4066)			
old-age pensioner	0.3 % (282/94413)	0.4 % (16/4066)			
other	9.7 % (9205/94413)	16.7 % (681/4066)			
Mother married/registered partner	74.9 % (70720/94423)	60.0 % (2441/4066)	< 0.001		

Table 1. Socioeconomic characteristics of mothers with 15-16 year old children in 2001, according to use of opioids in 2004-2009.

<sup>1</sup> Repeated use among the mothers equals 15+ prescriptions during 2004-2009 (Upper 10 percentile)

<sup>2</sup> 1764 missing (1.8 %)

<sup>3</sup> 10 missing (0.01 %)

	Repeated use of opioids among offspring (2004-2009) <sup>1</sup>						
	Prevalence % (n)	Unadjusted OR OR (95 % CI)	p-value	Adjusted OR <sup>2</sup> OR (95 % CI)	p-value		
Repeated maternal use of opioids <sup>3</sup>							
No	2.4 % (2172/92220)	1.0	-	1.0	-		
Yes	8.4 % (304/3599)	3.7 (3.3 – 4.2)	0.000	3.1 (2.7 – 3.6)	0.000		
Gender (offspring)							
Male	1.9 % (940/48940)	1.0	-	1.0	-		
Female	3.3 % (1536/46879)	1.7 (1.6 – 1.8)	0.000	1.7 (1.6 – 1.9)	0.000		
Mother's educational level							
High (college, university)	1.7 % (476/28011)	1.0	-	1.0	-		
Medium (senior high school)	2.8 % (1598/56530)	1.7 (1.5 – 1.9)	0.000	1.4 (1.3 – 1.6)	0.000		
Low (junior high school)	3.6 % (402/11278)	2.1 (1.9 – 2.4)	0.000	1.7 (1.4 – 1.9)	0.000		
Mother's activity status							
Employed (n = 80929)	2.4 % (1920/80278)	1.0	-	1.0	-		
Unemployed (n = 1241)	3.4 % (42/1225)	1.5 (1.1 – 2.0)	0.016	1.1 (0.8 – 1.5)	0.463		
Student (n = 1437)	2.8 % (40/1430)	1.2 (0.9 – 1.6)	0.245	1.0 (0.7 – 1.3)	0.864		
Old-age pensioner (n = 279)	3.6 % (10/275)	1.6 (0.9 – 2.9)	0.130	1.2 (0.6 – 2.2)	0.611		
Disability pensioner (n = 3800)	4.6 % (168/3688)	2.0 (1.7 – 2.4)	0.000	1.4 (1.2 – 1.6)	0.000		
Other (n = 9032)	3.3 % (296/8923)	1.4 (1.2 – 1.6)	0.000	1.1 (1.0 – 1.3)	0.033		
Mother married / registered partner							
Yes	2.3 % (1608/71169)	1.0	-	1.0	-		
No	3.5 % (868/24650)	1.6 (1.5 – 1.7)	0.000	1.4 (1.3 – 1.5)	0.000		

Table 2: Maternal opioid use, and other factors associated with use of opioids among offspring

<sup>1</sup> Repeated use among the offspring equals 4+ prescriptions during 2004-2009 (Upper 10 percentile)

 $^{2}$  Adjusted for gender, maternal use of opioids. mother's educational level, mother's activity status, age and if mother is married or has a registered partner

<sup>3</sup> Repeated use among the mothers equals 15+ prescriptions during 2004-2009 (Upper 10 percentile)

	Repeated use of NSAIDs among offspring (2004-2009) <sup>1</sup>						
-	Prevalence % (n)	Unajusted OR OR (95 % CI)	p-value	Adjusted OR <sup>2</sup> OR (95 % CI)	p-value		
Repeated mat. use of NSAIDs <sup>3</sup>							
No	5.1 % (4526/88824)	1.0	-	1.0	-		
Yes	9.4 % (661/6995)	1.9 (1.8 – 2.1)	0.000	1.8 (1.7 – 2.0)	0.000		
Gender (offspring)							
Male	3.6 % (1776/48940)	1.0	-	1.0	-		
Female	7.3 % (3411/46879)	2.1 (1.1 – 1.3)	0.000	2.1 (2.0 – 2.2)	0.000		
Mother's educational level							
High (college, university)	3.6 % (1021/28011)	1.0	-	1.0	-		
Medium (senior high school)	6.0 % (3399/56530)	1.7 (1.6 – 1.8)	0.000	1.6 (1.4 – 1-7)	0.000		
Low (junior high school)	6.8 % (767/11278)	1.9 (1.8 – 2.1)	0.000	1.7 (1.5 – 1.9)	0.000		
Mother's activity status							
Employed (n = 80929)	5.2 % (4200/80278)	1.0	-	1.0	-		
Unemployed (n = 1241)	5.5 % (67/1225)	1.0 (0.8 – 1.3)	0.721	0.9 (0.7 – 1.1)	0.354		
Student (n = 1437)	4.5 % (64/1430)	0.9 (0.7 – 1.1)	0.200	0.8 (0.6 – 1.0)	0.038		
Old-age pensioner (n = 279)	6.9 % (19/275)	1.3 (0.8 – 2.1)	0.226	1.2 (0.7 – 1.9)	0.447		
Disability pensioner (n = 3800)	8.0 % (296/3688)	1.6 (1.4 – 1.8)	0.000	1.4 (1.2 – 1.5)	0.000		
Other (n = 9032)	6.1 % (541/8923)	1.1 (1.0 – 1.3)	0.003	1.0 (0.9 – 1.1)	0.478		
Mother married / registered partner							
Yes	5.2 % (3669/71169)	1.0	-	1.0	-		
No	6.2 % (1518/24650)	1.2 (1.1 – 1.3)	0.000	1.1 (1.0 – 1.2)	0.001		

Table 3: Maternal use, and other factors associated with use of NSAIDs among offspring

\_

<sup>1</sup> Repeated use among the offspring equals 4+ prescriptions during 2004-2009 (Upper 10 percentile)

<sup>2</sup> Adjusted for gender, maternal use of NSAIDs. mother's educational level, mother's activity status, age and if mother is married or has a registered partner

<sup>3</sup> Repeated use among the mothers equals 15+ prescriptions during 2004-2009 (Upper 10 percentile)